EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Identification of circulating risk biomarkers for cognitive decline in a large community‐based population in Chongqing China

Yu Kang, Zijuan Feng, Qian Zhang, Mingjing Liu, Yanhua Li, Huan Yang, Lingling Zheng, Chunjiang Cheng, Weitao Zhou, Dandan Lou, Xiaoyong Li, Liangping Chen und 27 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.14443 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Yu Kang und 38 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, National Clinical Research Center for Child Health and Disorders, Ministr…. Hauptthemen laut MEDLINE: Biomarkers, Cognitive Dysfunction. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, CIHR, China Scholarship Council's Visiting Scholarship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION This study aims to investigate the relationship between blood‐based pathologies and established risk factors for cognitive decline in the community‐based population of Chongqing, a region with significant aging. METHODS A total of 26,554 residents aged 50 years and older were recruited. Multinomial logistic regression models were applied to assess the risk factors of cognition levels. Propensity score matching and linear mixed effects models were used to evaluate the relationship between key risk factors and the circulating biomarkers. RESULTS Shared and distinct risk factors for MCI and dementia were identified. Age, lower education, medical history of stroke, hypertension, and epilepsy influenced mild cognitive impairment (MCI) progression to dementia. Correlations between key risk factors and circulating neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), amyloid β protein (Aβ)40, and Aβ42/Aβ40 ratio suggest underlying mechanisms contributing to cognitive impairment. DISCUSSION The common and distinct risk factors across cognitive decline stages emphasize the need for tailored interventions. The correlations with blood biomarkers provide insights into potential management targets. Highlights From a large community‐based cohort study on the residents in Chongqing, we have identified that mild cognitive impairment (MCI) and dementia share several common risk factors, including age, female gender, rural living, lower education levels, and a medical history of stroke. However, each condition also has its own unique risk factors. Several factors contribute to the progression of MCI into dementia including age, education levels, occupation, and a medical history of hypertension and epilepsy. We discover the correlations between the risk factors for dementia and blood biomarkers that indicate the presence of axonal damage, glial activation, and Aβ pathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersCognitive DysfunctionHumansMaleFemaleChinaAgedRisk FactorsMiddle AgedAmyloid beta-PeptidesNeurofilament ProteinsCohort StudiesGlial Fibrillary Acidic ProteinAged, 80 and overDisease ProgressionDementiaPeptide Fragments

Stichwörter der Autor:innen

Alzheimer's diseaseblood biomarkersdementiaelderly populationmild cognitive impairment

Substanzen

BiomarkersAmyloid beta-PeptidesNeurofilament Proteinsneurofilament protein LGlial Fibrillary Acidic ProteinPeptide Fragments

Autor:innen und Institutionen

  • Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chil…
  • Townsend Family Laboratories, Department of Psychiatry, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Clinical Research Support Unit, BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
  • Department of Neurology and Center for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.
  • School of Public Health and Management, Chongqing Medical University, Chongqing, China.
  • Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Förderung

  • National Natural Science Foundation of China
  • CIHR
  • China Scholarship Council's Visiting Scholarship
  • Canadian Institutes of Health Research

Zitieren

APA

Kang, Y., Feng, Z., Zhang, Q., Liu, M., Li, Y., Yang, H., Zheng, L., Cheng, C., Zhou, W., Lou, D., Li, X., Chen, L., Feng, Y., Duan, X., Duan, J., Yu, M., Yang, S., Liu, Y., Wang, X., …, & Zhang, Y. (2025). Identification of circulating risk biomarkers for cognitive decline in a large community‐based population in Chongqing China. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14443

Vancouver

Kang Y, Feng Z, Zhang Q, Liu M, Li Y, Yang H, et al. Identification of circulating risk biomarkers for cognitive decline in a large community‐based population in Chongqing China. Alzheimer's & Dementia. 2025. doi:10.1002/alz.14443

BibTeX
@article{Kang2025,
  author = {Kang, Yu and Feng, Zijuan and Zhang, Qian and Liu, Mingjing and Li, Yanhua and Yang, Huan and Zheng, Lingling and Cheng, Chunjiang and Zhou, Weitao and Lou, Dandan and Li, Xiaoyong and Chen, Liangping and Feng, Yi and Duan, Xiaoling and Duan, Jianzhong and Yu, Mengjiao and Yang, Shou and Liu, Yuhang and Wang, Xin and Deng, Bo and Liu, Chenghui and Yao, Xiuqing and Zhu, Chi and Liang, Chunrong and Zeng, Xiaolong and Ren, Sisi and Li, Qunying and Zhong, Yin and Yan, Yong and Meng, Huaqing and Zhong, Zhaohui and Zhang, Yong and Kang, Jun and Luan, Xiaoqian and Pan, Sipei and Wu, Yili and Li, Tingyu and Song, Weihong and Zhang, Yun},
  title = {Identification of circulating risk biomarkers for cognitive decline in a large community‐based population in Chongqing China},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.14443}
}
Kostenlos starten →